INTRODUCTION
Crohn's disease is a chronic systemic disease that is associated with various extraintestinal manifestations (EIM). EIM of Crohn's disease are known to be associated with 20-40% of cases. 1 However, the incidence and prevalence of pulmonary involvement with Crohn's disease are variable in the literature and may be as low as 0.4%. 2 As pulmonary involvement of Crohn's disease is rare, there are no established therapeutic guidelines. In some case series reviews, infliximab treatment resulted in clinical and radiographic resolution of pulmonary EIM. 3 However, there have been no reports of improvement of pulmonary EIM after adalimumab monotherapy. Here, we present a very rare case of pulmonary involvement with Crohn's disease, which was recovered with adalimumab treatment.
CASE REPORT
A 35-year-old woman visited National Health Insurance
Service Ilsan Hospital with a 7 day history of pleuritic chest pain. She had been diagnosed with Crohn's disease 2 years prior. At that time, she had suffered from lower abdominal pain, diarrhea, and hematochezia. Initial colonoscopy find- Multiple small-sized ill-defined pulmonary nodules in bilateral lung fields with high fluorodeoxyglucose uptake of 3.88 to 8.88 peak standardized uptake value were observed on positron emission tomography CT (Fig. 3 ).
Surgical biopsy was required since malignancy could not be excluded. Thoracoscopic lung wedge resection was performed for diagnosis. In the surgical field findings, a whitish patch-like mucous-shaped lesion was observed in the left upper lobe surface area, and wedge resection was performed in the target area (Fig. 4A) . In gross examination of the surgical specimen, multiple necrotic lesions were noted (Fig. 4B ).
Necrotizing granulomatous inflammation with parenchymal geographical necrosis was detected in the biopsy specimen (Fig. 5A, B) . Organizing pneumonia was observed in a certain section of the tissue compartment (Fig. 5C) . The results of tuberculosis polymerase chain reaction and interferon-γ release assays were negative. Based on the patient's underlying disease, imaging, and pathological findings, the possibility of pulmonary EIM from Crohn's disease was considered.
Adalimumab therapy had been administered 10 times biweekly. Mycobacterial culture results at 6 and 8 weeks reported no growth.
At the 5 month follow-up visit, the patient did not have any clinical symptoms. The chest CT findings showed that the previously observed ill-defined pulmonary nodules had decreased significantly (Fig. 6 ). Radiologic and clinical remissions were confirmed. 
DISCUSSION
Pulmonary EIM of Crohn's disease are considered as rare manifestations despite increasing evidence suggesting frequent pulmonary involvement. 4 As the association between inflammatory bowel disease (IBD) and pulmonary involvement has not been well established, clinicians may underdiagnose pulmonary involvement in IBD patients. 5 Similarities in disease pathogenesis and the sharing of important environmental risk factors and genetic susceptibility suggest that there is complex interplay between IBD and airway diseases. Gut-associated lymphoid tissue shares some commonality in adhesion molecules necessary for homing of leukocytes to the mucosa with bronchiolar-associated lymphoid tissue. 5 However, the exact mechanism behind the link between lung and bowel abnormalities has not been clearly revealed.
According to reported case series and review articles, pulmonary EIM present a broad spectrum of pathological and radiological features. 3, 7 Imaging findings include multifocal patchy consolidation or ground-glass opacity with a subpleural or bronchovascular as well as mid to lower lung predominant distribution. 8 However, according to the case series review, radiographic findings of pulmonary involvement with
Crohn's disease showed various patterns without any definite specific findings. 3 There are no definite specific pathologic findings in distinguishing pulmonary EIM of Crohn's disease from other etiologies. Necrobiotic lung nodules that pathologically resemble those in rheumatoid arthritis (lung) and pyoderma gangrenosum (skin) have been described but are rare. 8 Necrotizing granulomatous inflammation with parenchymal geographical necrosis and organizing pneumonia detected in this case are known to be compatible with pulmonary EIM of Crohn's disease. In the lung pathology of this case, typical findings of necrotizing vasculitis often detected in Wegener granulomatosis were not observed. However, these findings are not unique to lung involvement of Crohn's disease. These histologic findings may also be present in vasculitis such as Wegener granulomatosis or pulmonary tuberculosis. 9, 10 Pathological reports without typical findings are not rare in the case of pulmonary Crohn's disease.
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Therefore, it is difficult to confirm pulmonary EIM of Crohn's disease with only pathological findings. As the spectrum of pathological and radiological patterns is broad, infection, especially tuberculosis, and drug-related changes should be considered in the differential diagnosis.
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In general, anti-tumor necrosis factor therapy is highly effective for EIM, except for primary sclerosing cholangitis. 12 However, pulmonary EIM are extremely rare, and there are not enough accumulated cases to establish standardized treatment guidelines. Eight cases of pulmonary EIM with Crohn's disease treated by infliximab were discovered through a literature review by Hayek et al. 3 All cases responded to infliximab therapy, resulting in clinical and radiographic resolution of the pulmo- nary IBD EIM. 3, 13 In the case of pulmonary EIM, a graded mixture of inhaled and oral corticosteroids can be also used, based on the nature of pulmonary involvement. 14 However, no corticosteroid was used in this case since concurrent infection could not be excluded. In this case, adalimumab monotherapy was used to treat pulmonary EIM of Crohn's disease.
According to a recent report, adalimumab is effective for achieving initial and durable resolution of all EIM of Crohn's diasease. 15 Adalimumab monotherapy does not seem to be inferior compared to a combination of adalimumab with other immunomodulators for induction and maintenance of remission and response with regards to Crohn's disease. 16 It is an unprecedented case of pulmonary Crohn's disease in which clinical and radiological remission has been achieved through adalimumab monotherapy.
In conclusion, we present a case of Crohn's disease with pulmonary EIM that resulted in radiological and clinical remission after adalimumab treatment. Considering anti-tumor necrosis factor treatment such as adalimumab and infliximab, infectious etiologies should be excluded through meticulous and tailored evaluations. When radiological abnormalities such as incidental lung nodules are detected in patients with Crohn's disease, pulmonary EIM should be included in differential diagnosis lists in addition to infections and malignancies.
